Forest plot of any fracture and osteoporotic fractures at 12 and 24 mo. Denosumab therapy did not demonstrate a significant difference in reducing the risk of (a) any type of fracture, (b) osteoporotic fracture at 12 mo, or (c) the risk of any type of fracture at 24 mo, but (d) denosumab was associated with a lower osteoporotic fracture incidence than bisphosphonate. BP, bisphosphonate; DMAb, denosumab; RR, risk ratio.